BUSCADOR RECOLECTA

Docosahexaenoic acid (DHA), the most abundant polyunsaturated fatty acid in the brain,
is essential for successful aging. In fact, epidemiological studies have demonstrated that increased
intake of DHA might lower the risk for developing Alzheimer’s disease (AD). These observations
are supported by studies in animal models showing that DHA reduces synaptic pathology and
memory deficits. Different mechanisms to explain these beneficial effects have been proposed;
however, the molecular pathways involved are still unknown. In this study, to unravel the main
underlying molecular mechanisms activated upon DHA treatment, the effect of a high dose of DHA
on cognitive function and AD pathology was analyzed in aged Tg2576 mice and their wild-type
littermates. Transcriptomic analysis of mice hippocampi using RNA sequencing was subsequently
performed. Our results revealed that, through an amyloid-independent mechanism, DHA enhanced
memory function and increased synapse formation only in the Tg2576 mice. Likewise, the IPA
analysis demonstrated that essential neuronal functions related to synaptogenesis, neuritogenesis, the
branching of neurites, the density of dendritic spines and the outgrowth of axons were upregulated
upon-DHA treatment in Tg2576 mice. Our results suggest that memory function in APP mice
is influenced by DHA intake; therefore, a high dose of daily DHA should be tested as a dietary
supplement for AD dementia prevention., Grant funding support from the Ministry of Science and Innovation (MINECO) with exp. PID2019-104921RB-I00/MCI/AEI/10.13039/501100011033. Foundation for Applied Medical Research, the University of Navarra (Pamplona, Spain) for financial support and the Asociación de Amigos of the University of Navarra for the grant to S.B.

Despite the well-accepted role of the two main neuropathological markers (β-amyloid and tau) in the progression of Alzheimer’s disease, the interaction and specific contribution of each of them is not fully elucidated. To address this question, in the present study, an adeno-associated virus (AAV9) carrying the mutant P301L form of human tau, was injected into the dorsal hippocampi of APP/PS1 transgenic mice or wild type mice (WT). Three months after injections, memory tasks, biochemical and immunohistochemical analysis were performed. We found that the overexpression of hTauP301L accelerates memory deficits in APP/PS1 mice, but it did not affect memory function of WT mice. Likewise, biochemical assays showed that only in the case of APP/PS1-hTauP301L injected mice, an important accumulation of tau was observed in the insoluble urea fraction. Similarly, electron microscopy images revealed that numerous clusters of tau immunoparticles appear at the dendrites of APP/PS1 injected mice and not in WT animals, suggesting that the presence of amyloid is necessary to induce tau aggregation. Interestingly, these tau immunoparticles accumulate in dendritic mitochondria in the APP/PS1 mice, whereas most of mitochondria in WT injected mice remain free of tau immunoparticles. Taken together, it seems that amyloid induces tau aggregation and accumulation in the dendritic mitochondria and subsequently may alter synapse function, thus, contributing to accelerate cognitive decline in APP/PS1 mice., ) to J.F.-I. and E.S and from the Department of Economic and Business Development from Government of Navarra (INNOLFACT project; Ref. 0011-1411-2020-000028).We gratefully acknowledge grant funding support from Ministry of Science and Innovation (MINECO) with exp. PID2019-104921RB-I00/MCI/AEI/10.13039/501100011033as well as to the Foundation for Applied Medical Research, the University of Navarra (Pamplona, Spain) for financial support and the Asociación de Amigos of the University of Navarra for the grant to M.P.-G. and S.B. We also gratefully acknowledge grant funding support from Spanish Ministerio de Economía y Competitividad (RTI2018-095812-B-I00 MCIN/ AEI/10.13039/501100011033) y por FEDER una manera de hacer Europa and Junta de Comunidades de Castilla-La Mancha (SBPLY/17/180501/000229) to RL, from the Spanish Ministry of Science Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033

A complex network of interactions exists between the olfactory, immune and central nervous systems. In this work we intend to investigate this connection through the use of an immunostimulatory odorant like menthol, analyzing its impact on the immune system and the cognitive capacity in healthy and Alzheimer’s Disease Mouse Models. We first found that repeated short exposures to menthol odor enhanced the immune response against ovalbumin immunization. Menthol inhalation also improved the cognitive capacity of immunocompetent mice but not in immunodeficient NSG mice, which exhibited very poor fear-conditioning. This improvement was associated with a downregulation of IL-1β and IL-6 mRNA in the brain´s prefrontal cortex, and it was impaired by anosmia induction with methimazole. Exposure to menthol for 6 months (1 week per month) prevented the cognitive impairment observed in the APP/PS1 mouse model of Alzheimer. Besides, this improvement was also observed by the depletion or inhibition of T regulatory cells. Treg depletion also improved the cognitive capacity of the APPNL-G-F/NL-G-F Alzheimer´s mouse model. In all cases, the improvement in learning capacity was associated with a downregulation of IL-1β mRNA. Blockade of the IL-1 receptor with anakinra resulted in a significant increase in cognitive capacity in healthy mice as well as in the APP/PS1 model of Alzheimer´s disease. These data suggest an association between the immunomodulatory capacity of smells and their impact on the cognitive functions of the animals, highlighting the potential of odors and immune modulators as therapeutic agents for CNS-related diseases., This work was supported by a grant from the Ministry of Science and Innovation (PID2021-128283OA-I00 financed by MCIN/ AEI /10.13039/501100011033 and by FEDER A way of making Europe and PID2019-104921RB-I00), Department of Economic and Business Development from the Government of Navarra (INNOLFACT project; Ref. 0011-1411-2020-000028) and Explora grant from Ministry of Economy and Competitiveness, (SAF2013-50067-EXP to JL).